^
9d
Pancreatic Solitary Fibrous Tumor: A Common Tumor Occurring in a Rare Location. (PubMed, Am J Case Rep)
Histologically, given its morphological diversity, it needs to be differentiated from spindle cell tumors such as pancreatic gastrointestinal stromal tumors, fibromatosis, inflammatory myofibroblastic tumors, and pancreatic sclerosing epithelioid fibrosarcoma. Nuclear expression of STAT6 and the presence of NAB2: : STAT6 fusion are important characteristics of SFT.
Journal
|
STAT6 (Signal transducer and activator of transcription 6) • NAB2 (NGFI-A Binding Protein 2)
9d
Effects of short- and long-term mutant IDH1 inhibition on radiosensitivity across genetically diverse patient-derived IDH1-mutant glioma cells. (PubMed, Neurooncol Adv)
We investigated the effects of short-term (5 days) and long-term (≥5 weeks) exposure to the IDH1 inhibitor AGI-5198 on radiation-induced cytotoxicity...Effects were comparable to short-term treatment, while radiation responses varied by genetic context. No deleterious interaction between IDHi and IR was observed in endogenous IDH-mutant cells except for MGG18 Tet+ supporting integration of IDHi with radiotherapy in IDH mutant gliomas.
Journal • BRCA Biomarker
|
MET (MET proto-oncogene, receptor tyrosine kinase) • BRCA2 (Breast cancer 2, early onset) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1)
|
BRCA2 mutation • IDH1 mutation • IDH1 R132
|
AGI-5198
16d
Maxillary mesenchymal chondrosarcoma harboring HEY1::NCOA2 fusion in a 13-year-old girl: a rare case report and literature review. (PubMed, Front Pediatr)
The patient was treated with VAC chemotherapy (vincristine, actinomycin D, cyclophosphamide), local radiotherapy (60 Gy), cranial prophylactic radiotherapy (12 Gy), and subsequent debulking surgery. Multimodal treatment incorporating chemotherapy, radiotherapy, surgery, and targeted maintenance therapy can achieve meaningful disease control in aggressive craniofacial MCS. To our knowledge, this represents one of the very few reported pediatric cases of maxillary MCS with confirmed HEY1::NCOA2 fusion managed with sirolimus-based maintenance therapy.
Journal
|
NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • ETV6 (ETS Variant Transcription Factor 6) • CD34 (CD34 molecule) • VIM (Vimentin) • HEY1 (Hes Related Family BHLH Transcription Factor With YRPW Motif 1) • NCOA2 (Nuclear Receptor Coactivator 2)
|
cyclophosphamide • vincristine • sirolimus • dactinomycin
22d
Enhancement of Lysosomal Biogenesis in the HCT116 Cells Treated with Doxorubicin under Normoxic Conditions. (PubMed, Biochemistry (Mosc))
Hydrophobic weakly basic drugs, such as doxorubicin and sunitinib, are currently key components of cancer chemotherapy...Co-treatment with doxorubicin and chloroquine, a well-established lysosomotropic agent, results in the increased lysosomal volume under both normoxic and hypoxic conditions...A similar effect, lysosomal volume expansion and enhanced degradative capacity in response to doxorubicin, was also observed in the human fibrosarcoma cell line HT1080. In summary, this study provides the first evidence that doxorubicin directly modulates lysosomal parameters in the tumor cell lines under varying oxygen concentrations.
Journal
|
TFEB (Transcription Factor EB 2)
|
sunitinib • doxorubicin hydrochloride • chloroquine phosphate
23d
Inhibition of MAFB and PI3K/AKT Signaling for Hereditary FSGS with Multicentric Carpotarsal Osteolysis. (PubMed, J Am Soc Nephrol)
Our findings demonstrate that the MCTO mutation results in MAFB protein accumulation and leads to the development of FSGS in mice. These findings identify the MAFB-PI3K/AKT pathway as a key mechanism underlying MCTO-associated nephropathy.
Journal
|
IGF1 (Insulin-like growth factor 1) • MAFB (MAF BZIP Transcription Factor B) • MAF (MAF BZIP Transcription Factor)
|
imatinib
1m
HMGA2 expression in CIC-rearranged sarcoma and other small round/epithelioid cell tumours. (PubMed, Histopathology)
HMGA2 may be more readily implemented than ETV4 and DUX4, even in non-specialized hospitals. Thus, HMGA2 immunohistochemistry is a useful adjunct for CRS diagnosis. HMGA2 expression in CRS and other small round or epithelioid cell tumours should be tested in a larger series, particularly in non-DUX4 CRS and ATXN1/ATXN1L-rearranged sarcomas.
Journal
|
WT1 (WT1 Transcription Factor) • EWSR1 (EWS RNA Binding Protein 1) • GLI1 (GLI Family Zinc Finger 1) • ATXN1L (ataxin 1 like) • FOSL1 (FOS Like 1) • HMGA2 (High mobility group AT-hook 2) • GATA3 (GATA binding protein 3) • DUX4 (Double Homeobox 4) • ETV4 (ETS Variant Transcription Factor 4) • MUC5AC (Mucin 5AC)
1m
c-MAF Transcriptionally Activates Slc40a1 to Repress Ferroptosis in Sepsis-Associated Encephalopathy. (PubMed, CNS Neurosci Ther)
Our findings suggest that c-MAF/Slc40a1 may represent a promising prevention target for SAE.
Journal
|
SLC40A1 (Solute Carrier Family 40 Member 1)
1m
Neutralization of acyl-CoA-binding protein attenuates glucocorticoid-mediated suppression of cancer immunosurveillance. (PubMed, Proc Natl Acad Sci U S A)
Here, we identify the acyl-CoA-binding protein/diazepam-binding inhibitor (ACBP/DBI) as a critical effector of the GC-induced suppression of tumor immunosurveillance and immunotherapy efficacy...The immunosuppressive activity of GCs and the immunostimulatory function of anti-ACBP/DBI mAb converge on Tsc22d3 expression in myeloid cells, as shown by loss-of-function experiments in myeloid-specific Tsc22d3-deficient mice. These findings reveal ACBP/DBI as a central mediator of GC-induced immune evasion and suggest its neutralization as a therapeutic strategy to restore anticancer immunity during endogenous or iatrogenic GC exposure.
Journal • PD(L)-1 Biomarker • IO biomarker
|
TSC22D3 (TSC22 Domain Family Member 3)
1m
Trial completion date
|
doxorubicin hydrochloride • pazopanib • cyclophosphamide • ifosfamide • daunorubicin
1m
Novel EPS15::KLF17 and EPS15L1::KLF17 Fusions Define a Distinctive Group of MUC4-Positive Spindled to Epithelioid Sarcomas. (PubMed, Am J Surg Pathol)
EPS15/EPS15L1::KLF17-rearranged sarcoma has distinctive histologic findings, including diffuse MUC4 expression. Recognition is clinically important given its potential for late recurrence and metastasis.
Journal
|
EWSR1 (EWS RNA Binding Protein 1) • CD24 (CD24 Molecule) • MUC4 (Mucin 4, Cell Surface Associated)
1m
DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2) (clinicaltrials.gov)
P3, N=400, Recruiting, Day One Biopharmaceuticals, Inc. | Trial completion date: Mar 2030 --> Jun 2031 | Trial primary completion date: Feb 2026 --> Jun 2027
Trial completion date • Trial primary completion date
|
carboplatin • Ojemda (tovorafenib)
1m
Emerging Molecular Defined Bone and Soft Tissue Diagnoses: When Do They Matter? (PubMed, Mod Pathol)
This review aims to highlight the key clinicopathologic features of these tumors to facilitate accurate diagnosis, discuss ancillary studies that assist in navigating the differential diagnoses, and outline strategies to avoid common diagnostic pitfalls. Finally, we emphasize when molecular characterization may be necessary to guide diagnosis and support appropriate clinical management.
Review • Journal
|
CD34 (CD34 molecule)